How to Treat Bipolar Disorder: Medications and Therapy

Treating bipolar disorder almost always requires medication as the foundation, with structured psychotherapy layered on top to improve long-term stability. No single pill or therapy session handles every phase of the illness, because bipolar disorder cycles between mania (or its milder form, hypomania) and depression, and a treatment that controls one pole can sometimes worsen the other. The combination of mood-stabilizing drugs and evidence-based therapy gives people the best shot at fewer relapses and a more functional life, but the specifics depend on which phase someone is in, how they respond to particular drugs, and what they can tolerate over years of use.

Mood Stabilizers

Lithium remains the most thoroughly studied medication for bipolar disorder and is still considered a first-line option for both acute mania and long-term maintenance. Beyond controlling mood episodes, lithium has a distinct property that sets it apart from every other psychiatric drug: it lowers the risk of suicide. Research shows this effect holds even when mood stabilization is incomplete and blood levels are below the typical therapeutic range.¹ A large study found that patients who filled lithium prescriptions at least twice had roughly half the suicide rate of those who filled it only once, and the risk continued to drop with each additional prescription filled.² That anti-suicide benefit is one reason lithium often stays in the conversation even when other drugs might control mood swings equally well.

Two anticonvulsant medications also play important roles. Valproate (often prescribed as divalproex) is effective for acute mania and appears relatively safe in the maintenance phase, meaning it doesn’t tend to trigger a swing into depression once the manic episode resolves. Lamotrigine is the only anticonvulsant with proven efficacy specifically in acute bipolar depression, filling a gap that lithium and valproate don’t cover as reliably.³ In practice, many clinicians use lamotrigine as a go-to for patients whose depression is the dominant problem, and valproate or lithium when mania is the bigger concern.

Antipsychotics for Different Phases

A group of newer antipsychotic medications has become central to bipolar treatment, especially for acute mania. Drugs such as olanzapine, risperidone, quetiapine, aripiprazole, and ziprasidone all show comparable effectiveness for manic episodes, and they can be used alone or combined with a mood stabilizer like lithium or valproate.⁴ Where these medications diverge from each other is in treating bipolar depression, which has historically been harder to manage than mania.

A network meta-analysis comparing these drugs head-to-head for bipolar depression found that lurasidone, quetiapine, olanzapine, and cariprazine all outperformed placebo. Of those, lurasidone had the lowest number needed to treat for a meaningful response, meaning fewer patients needed to take it before one experienced a clear benefit. Quetiapine was close behind.⁵ Cariprazine is one of the newest options, approved for both acute mania and bipolar I depression, including patients who have mixed features where manic and depressive symptoms overlap.⁶

The choice among these drugs often comes down to side effects rather than raw effectiveness. Quetiapine causes more sedation. Olanzapine is strongly associated with weight gain. Lurasidone tends to be better tolerated metabolically but can cause restlessness. These trade-offs matter enormously because bipolar treatment is lifelong, and a drug someone can’t stand taking for more than six months isn’t a real solution.

Why Antidepressants Are Complicated in Bipolar Disorder

Using a standard antidepressant for bipolar depression sounds intuitive but comes with a serious risk: flipping the patient into a manic episode. A large retrospective study found that all antidepressant classes were associated with an increased incidence of mania, with SSRIs and venlafaxine showing a clear statistical signal.⁷ The risk is most dangerous when antidepressants are prescribed alone. One study found that the hazard of switching into mania was nearly three times higher in patients on antidepressant monotherapy compared to those taking a mood stabilizer alongside the antidepressant. When a mood stabilizer was present, no increase in mania risk was observed during the first three months, and the risk actually decreased over the following six months.⁸

The concern extends to younger patients as well. A study of children and adolescents with unipolar depression found that antidepressant use was associated with a small but statistically meaningful increase in manic episodes by one year of follow-up.⁹ This is one reason clinicians are cautious about antidepressants in anyone who might have unrecognized bipolar disorder. When antidepressants are used in bipolar depression, the standard approach is to always pair them with a mood stabilizer or antipsychotic and to discontinue them relatively quickly once the depressive episode lifts.

Therapy That Complements Medication

Medication controls the biology of bipolar disorder, but therapy addresses everything medication cannot: recognizing early warning signs, managing stress, repairing relationships strained by mood episodes, and building daily habits that reduce the chance of relapse. Several structured approaches have strong evidence behind them.

Cognitive Behavioral Therapy

CBT is recommended as an add-on therapy in all phases of bipolar disorder except acute mania, when people are generally too activated to engage productively in talk therapy.¹⁰ A meta-analysis of randomized trials found that CBT reduced relapse rates, improved mania severity, and boosted day-to-day functioning.¹¹ That said, the benefits may diminish over time. A separate meta-analysis found significant short-term effects on relapse at six months but noted these effects weakened with longer follow-up, and the impact on depression specifically was less clear.¹² The practical takeaway is that CBT works best when used consistently, not as a one-time course you complete and put on the shelf.

Interpersonal and Social Rhythm Therapy

IPSRT was designed specifically for bipolar disorder, built on the observation that disrupted daily routines, irregular sleep, and unstable social schedules can destabilize mood. The therapy focuses on helping patients regulate their daily rhythms: eating, sleeping, exercising, and socializing at consistent times. Two large controlled trials have supported IPSRT as both an acute intervention and a long-term preventive strategy for bipolar I and II.¹³ A randomized controlled study found that patients receiving IPSRT showed significant reductions in both depression and mania scores while also achieving better regulation of their biological rhythms.¹⁴

Family-Focused Therapy

Bipolar disorder doesn’t happen in isolation. Mood episodes ripple through families, and the emotional climate at home can either protect against or trigger relapse. Family-focused therapy (FFT) brings family members into treatment to improve communication, reduce conflict, and educate everyone about the illness. Across eight randomized controlled trials with both adults and adolescents, FFT combined with mood stabilizers sped up recovery from mood episodes and reduced recurrences compared to briefer education-only approaches over one to two years. The benefits were especially strong in families with high levels of emotional tension or criticism.¹⁵ Even a condensed version of FFT delivered over a few weeks has shown reductions in family stress and improvements in patient functioning that lasted nine to ten months.¹⁶

Side Effects and Long-Term Monitoring

Every effective bipolar medication comes with side effects that require ongoing attention, and these side effects are a major reason people stop taking their drugs. Lithium’s most significant long-term concern is its effect on the kidneys. In one long-term study, about 30% of patients on lithium experienced at least one episode of reduced kidney function, mostly after 15 or more years of treatment and after age 55. Kidney filtering capacity declined by roughly 1% per year of treatment. None of the patients in that study, however, reached end-stage kidney failure.¹⁷ Lithium also raises the risk of thyroid problems and elevated calcium levels.

A population-based study comparing lithium to valproate, olanzapine, and quetiapine found that those three alternatives all had lower rates of kidney disease, thyroid dysfunction, and high calcium compared to lithium. But the trade-off was real: all three carried significantly higher rates of substantial weight gain, and olanzapine was also associated with elevated blood pressure.¹⁸ There is no free lunch in bipolar pharmacology. You and your doctor are always choosing which set of risks you’d rather manage. Regular blood work, including kidney function, thyroid levels, metabolic panels, and lithium blood levels where applicable, is non-negotiable for long-term treatment.

The Adherence Problem

Roughly half of people with bipolar disorder stop taking their medication during long-term treatment, a rate that has stayed stubbornly consistent over the years and is similar to other chronic conditions like diabetes or hypertension.¹⁹ Some estimates suggest that more than 60% are at least partially nonadherent, meaning they skip doses, adjust their own timing, or take extended breaks from medication. Stopping mood stabilizers places patients at high risk for relapse.²⁰

People stop for many reasons: side effects they haven’t discussed with their doctor, feeling fine and questioning whether they still need medication, the stigma of a psychiatric diagnosis, or simply not believing the drugs are helping. Research into what actually improves adherence points to therapies that feature a collaborative relationship between patient and clinician, good education about the illness and medications, and active involvement from family or partners.²¹ This is one of the strongest arguments for adding structured therapy to any medication plan. The therapy itself may improve adherence, which in turn keeps the medication working.

Treating Bipolar Disorder in Children and Adolescents

Pediatric bipolar disorder presents unique challenges. Newer antipsychotics tend to show stronger improvement in manic symptoms compared to lithium or anticonvulsants in younger patients, but they also cause more weight gain and sedation.²² Using a single mood stabilizer alone has not demonstrated effectiveness for long-term remission in youth. Evidence suggests that combining two mood stabilizers, or a mood stabilizer with an antipsychotic, yields better results for children with bipolar I, especially those with acute mania and psychotic features.²³ The weight gain issue is particularly concerning for young patients facing decades of treatment, so metabolic monitoring and lifestyle interventions need to start early.

Pregnancy and Postpartum Planning

Women with bipolar disorder face difficult decisions around pregnancy because several key medications pose risks to a developing fetus. Valproate and carbamazepine carry high teratogenicity risk and should generally be avoided in women who could become pregnant.²⁴ The postpartum period is extremely dangerous for relapse. A meta-analysis found that women who were medication-free during pregnancy had a postpartum relapse rate of about 66%, compared to roughly 23% for those who maintained prophylactic medication.²⁵

That stark difference underscores why perinatal planning is critical. Experts recommend creating a written relapse prevention plan that covers which medications to maintain or substitute during pregnancy, how to handle the immediate postpartum weeks, strategies for protecting sleep and circadian rhythm after delivery, and how to recognize early warning signs of relapse.²⁴ Women with a history of isolated postpartum psychosis may benefit from starting prophylactic medication immediately after delivery, even if they chose to avoid medication during pregnancy.

When Standard Treatments Are Not Enough

Some people with bipolar disorder do not respond adequately to multiple rounds of medication and therapy. For treatment-resistant cases, electroconvulsive therapy (ECT) is one of the most effective options available. A study of over 500 patients with severe, drug-resistant bipolar disorder found that roughly 69% responded to ECT, with the highest rates in patients with catatonic features (about 81%) and mixed states (about 73%).²⁶ In a head-to-head randomized trial comparing ECT to optimized pharmacological treatment for bipolar depression, the ECT group had a response rate of about 74% versus 35% for the medication-adjustment group.²⁷ Despite its effectiveness, ECT still carries a “last resort” reputation that many researchers and clinicians feel is outdated. For severely ill patients who aren’t responding to drugs, waiting through several more failed medication trials before considering ECT costs time and suffering.

Repetitive transcranial magnetic stimulation (rTMS), which uses magnetic pulses to stimulate specific brain regions, is also being studied for bipolar depression. A pilot study reported remission rates above 70% and response rates above 85% with no induced manic episodes or other serious adverse events.²⁸ Research in older adults found that both unipolar and bipolar patients responded similarly to an accelerated rTMS protocol.²⁹ These results are promising but still come from small studies, so rTMS is not yet a standard recommendation for bipolar depression in the way it is for unipolar treatment-resistant depression.

Ketamine, the fast-acting antidepressant that has transformed treatment-resistant unipolar depression, is under investigation for bipolar depression as well. Reports suggest it may reduce suicidal thinking, anhedonia, and anxiety in bipolar patients.³⁰ The concern with ketamine in bipolar disorder is the potential for triggering mania or psychosis, so its use is typically only considered under close supervision when other approaches have failed.

Light Therapy and Circadian Rhythm Management

Bipolar disorder has a deeply entangled relationship with circadian rhythms and sleep. Disrupted sleep is both a symptom and a trigger, and the depressive episodes that account for most of the disability burden in bipolar disorder are often tied to circadian dysregulation. Bright light therapy, already established for seasonal depression, has shown striking results for bipolar depression when used carefully. A randomized, double-blind trial found that midday bright light therapy achieved a remission rate of about 68%, compared to roughly 22% for a placebo light, with no mood switches into mania.³¹ The timing matters: morning light therapy has been linked to manic switches in some patients, which is why midday exposure is preferred in bipolar depression.

Beyond the light box, lifestyle habits that stabilize circadian rhythms appear to be genuinely protective. Higher daytime light exposure, regular physical activity, consistent sleep schedules, and maintaining a steady rhythm of daily activities have all been associated with fewer depressive episodes. The International Society for Bipolar Disorders recommends spending ample time outdoors during the day, maintaining regular exercise, keeping consistent bedtimes, and enforcing a digital screen curfew about an hour before sleep.³² None of these habits replace medication, but they help hold gains in place and may reduce the frequency of depressive dips.

Supplements and Nutritional Add-Ons

Given the side effects of standard medications, many patients wonder about natural supplements. The two that have attracted the most research attention for bipolar depression are omega-3 fatty acids and N-acetylcysteine (NAC). A systematic review of clinical trials found positive evidence for NAC and for a chelated mineral-vitamin formula when added to standard medication, with large effect sizes for both.³³ Evidence for omega-3s is mixed but leans positive for bipolar depression specifically, with no support for benefit in mania.³⁴

The honest assessment, though, is that these findings are preliminary and inconsistent. A separate review concluded that the evidence does not support the routine use of nutritional supplements for treating or preventing bipolar depression.³⁵ Supplements should not replace proven medications, and they should be discussed with a prescriber because even “natural” compounds can interact with psychiatric drugs. That said, adding omega-3s or NAC alongside a solid medication regimen is a reasonable conversation to have with your doctor if depressive symptoms remain burdensome.

Smartphone Tools and Self-Monitoring

Digital self-management tools have arrived in bipolar care, and the results so far are nuanced. A large randomized trial tested a smartphone-based self-management system for people with bipolar disorder and found that it did not reduce overall relapse risk for the full group. However, patients classified as lower-risk at baseline did see a significant reduction in relapse, lower manic symptom severity, and better relational quality of life. Higher-risk patients showed no benefit from the app.³⁶ Across the full sample, the app did reduce depressive symptom severity. The implication is that digital tools may work best as an early-intervention and self-monitoring layer for people who are already relatively stable, rather than as a safety net for those in active crisis.

Pharmacogenomic Testing

Genetic testing to guide medication choice is already established in some areas of medicine, but it remains in early stages for bipolar disorder. The idea is straightforward: if a blood test could predict whether you’ll respond well to lithium or metabolize quetiapine too quickly, you could skip months of trial-and-error prescribing. A study in Chinese patients found that pharmacogenomic-guided treatment reduced the number of medications needed and achieved better outcomes at 4, 8, and 12 weeks with fewer side effects compared to standard prescribing.³⁷ Genome-wide studies of lithium response have produced promising leads as well.³⁸

Still, no gene identified from lithium-response studies has been included in any FDA-approved test for drug efficacy. Genetic information has, however, been incorporated into drug labels for the safety of carbamazepine and valproate. Carbamazepine carries a known risk of a dangerous skin reaction in people with a specific genetic variant common in some Asian populations, and testing for that variant before prescribing is now standard practice. The broader vision of genetically tailored bipolar treatment is plausible but not yet routine, and the clinical applicability of current pharmacogenomic testing in psychiatry lags well behind what’s available in fields like oncology.³⁹